FDA approved extending dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneration and diabetic patients. The approval reduces treatment burden and could boost adherence and competitive positioning for Regeneron, representing a modestly positive commercial catalyst for the company.
FDA approved extending dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneration and diabetic patients. The approval reduces treatment burden and could boost adherence and competitive positioning for Regeneron, representing a modestly positive commercial catalyst for the company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
